CytoMed Therapeutics Limited (GDTC)

CytoMed Therapeutics Balance Sheet

Financials in millions SGD. Fiscal year is January - December.

Year	2023	2022	2021	2020
Cash & Equivalents	9	1.58	2.51	0.89
Cash & Cash Equivalents	9	1.58	2.51	0.89
Cash Growth	469.41%	-37.13%	183.84%	-
Receivables	1.1	0.91	0.77	0.58
Total Current Assets	10.1	2.49	3.28	1.47
Property, Plant & Equipment	2.06	2.47	2.5	2.3
Long-Term Investments	0.2	0.24	0.27	0
Goodwill and Intangibles	0.01	0.02	0.03	0.05
Total Long-Term Assets	2.27	2.73	2.8	2.35
Total Assets	12.37	5.23	6.08	3.82
Accounts Payable	0.52	0.42	0.22	0.35
Deferred Revenue	0.01	0	0.01	0.01
Current Debt	0.04	3.74	2.7	2.37
Other Current Liabilities	0.15	0	0	0
Total Current Liabilities	0.72	4.17	2.94	2.73
Long-Term Debt	0.41	0.48	0.55	0.61
Total Long-Term Liabilities	0.41	0.48	0.55	0.61
Total Liabilities	1.12	4.64	3.49	3.34
Total Debt	0.45	4.22	3.26	2.98
Debt Growth	-89.38%	29.48%	9.32%	-
Retained Earnings	-12.33	-8.2	-5.07	-3.02
Comprehensive Income	-0.22	-0.13	-0.03	-0.01
Shareholders' Equity	11.25	0.59	2.59	0.48
Net Cash / Debt	8.55	-2.64	-0.75	-2.1
Net Cash Per Share	0.80	-0.33	-0.11	-0.36
Working Capital	9.38	-1.67	0.35	-1.26
Book Value Per Share	1.06	0.07	0.37	0.08

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).